Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030535

Enrollment

Unknown

Registered

2020-03-06

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid

control group:interferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Real-time fluorescence RT-PCR detection of nucleic acid positive of novel coronavirus in respiratory tract specimens or blood preparation; 3. Sequencing of virus genes in respiratory tract specimens or blood preparation, highly homologous to known novel coronavirus ; 4. The patients are diagnosed with common type of novel coronavirus pneumonia according to the Pneumonia Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6), and have fever and/or respiratory symptoms, and shows pneumonia in the chest CT. 5. Can be included in some severe patients, consistent with any of the following: (1) Respiratory distress, RR >= 30 times/min; (2) Under quiescent condition, Oxygen saturation <= 93%; (3) Arterial partial pressure of oxygen(PaO2)/oxygen concentration(FiO2)<= 300mmHg.

Exclusion criteria

Exclusion criteria: (1) Combined with high blood pressure, diabetes, coronary heart disease and other underlying disease; (2) Combined with malignant tumor or a medical history of malignant tumor; (3) Pregnant or lactating women; (4) Suffering from severe mental illness; (5) Medical history of unstable angor pectoris or myocardial?infarction within 6 months, coronary arteriography; it indicates severe stenosis of the main branch of the coronary artery; (6) Medical history of cerebral infarction or cerebral hemorrhage within 6 months; (7) Intolerant or allergic to interferon preparations; (8) The investigator determined that the patients were not eligible for the trial.

Design outcomes

Primary

Measure	Time frame
Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);	—

Secondary

Measure	Time frame
All-cause death;Adverse events;	—

Countries

China

Contacts

Public ContactXu Zhihua

Mianyang Central Hospital

1121733818@qq.com+86 18508160990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026